Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on May 31, 2023. The filing discloses topline results from recent pilot studies for the Company's product candidate, Anaphylm™ (epinephrine) Sublingual Film, intended for the treatment of severe allergic reactions including anaphylaxis. These studies were conducted following the Company's End-of-Phase 2 meeting with the FDA.
Key Financial Metrics
This filing is a disclosure of clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Clinical Results
The filing details significant pharmacokinetic (PK) and pharmacodynamic (PD) data from the Pilot Studies:
- Administration Optimization: Revised instructions eliminated hold time periods, resulting in a geometric mean maximum epinephrine concentration (Cmax) of 400pg/mL and a median time to maximum concentration (Tmax) of 10 minutes (range 5-20 minutes), the fastest median Tmax to date for the program.
- Comparative Performance: Epinephrine levels for Anaphylm were higher than a 0.3mg manual injection at all timepoints within the first 10 minutes. All but one subject exceeded 100 pg/mL by 15 minutes.
- Auto-Injector Comparison: The study compared Anaphylm to Auvi-Q®, EpiPen®, and a generic equivalent. Geometric mean Cmax levels for these auto-injectors were 646, 628, and 573pg/mL, respectively, with median Tmax times of 30, 10, and 15 minutes.
- Repeat Dosing: A repeat dose administered 25 minutes after the initial dose produced a median Tmax of 8 minutes, with Cmax and exposure comparable to auto-injectors, demonstrating effectiveness for a second dose.
- Safety and Tolerability: Anaphylm was well-tolerated with no serious adverse events. A median increase of 22mmHg in systolic blood pressure was observed at 2 minutes, maintained for 1 hour.
Guidance, Outlook, and Risks
Outlook and Next Steps:
- The Company expects to refine administration instructions in an ongoing pilot study (AQ109103).
- Finalization of the pivotal study protocol for FDA submission and alignment is expected in Q3 2023.
- Execution of the pivotal study is expected to begin in Q4 2023.
Risks and Contingencies:
- Regulatory Risk: There is no assurance of FDA approval. The FDA may require additional clinical studies, and the Company must address concerns from the End-of-Phase 2 meeting.
- Financial Risk: Risks include insufficient capital and cash resources to fund future clinical development activities.
- Development Risk: Early trial data may not be indicative of final results; delays in site initiation, enrollment, or supply chain issues could impact timelines.
- Market Risk: Uncertainty regarding market acceptance and competition from existing products.
Key Facts for Investor Verification
- Verify the Company's current cash position and runway to fund the pivotal study expected to begin in Q4 2023, as this filing contains no financial data.
- Confirm the specific FDA feedback received during the End-of-Phase 2 meeting that necessitated these pilot studies.
- Monitor the timeline for the submission of the pivotal study protocol in Q3 2023 and any potential delays.
- Assess the competitive landscape regarding the Cmax and Tmax performance of Anaphylm versus approved auto-injectors (EpiPen, Auvi-Q) as detailed in the study.
- Review the "Risk Factors" section in the Company's most recent Form 10-K or 10-Q for a comprehensive list of operational and financial risks.